Diabetes Care, Vol 19, Issue 5 486-493, Copyright © 1996 by American Diabetes Association

ARTICLES

Evolution, risk factors, and prognostic implications of albuminuria in NIDDM

LK Niskanen, I Penttila, M Parviainen and MI Uusitupa
Department of Clinical Nutrition, University of Kuopio, Finland. iniskane@messi.uku.fi

OBJECTIVE--To study the cumulative incidence of albuminuria and its determinants in NIDDM patients and nondiabetic subjects from the diagnosis and impact of albuminuria on cardiovascular mortality. RESEARCH DESIGN AND METHODS--We performed a 10-year prospective observational study of 133 well-characterized middle-aged patients with newly diagnosed NIDDM and 144 control subjects. Both groups were examined at baseline and after 5 and 10 years. Urinary albumin excretion was determined from timed 24-h (baseline and 5-year examinations) or overnight samples (10-year examination). Microalbuminuria was defined as urinary albumin excretion of 30-300 mg/24 hr or 20-200 micrograms/min, with the higher values considered as macroalbuminuria. RESULTS--The cumulative incidence of micro- and macroalbuminuria increased sharply after 5 years in NIDDM patients (baseline: 18.2 and 3.0%; 5 years: 18.9 and 1.8%; and 10 years: 33.0 and 10.2%) but markedly less in control subjects (baseline: 1.4 and 0%, P < 0.001 for diabetic patients vs. control subjects for any albuminuria; 5 years: 6.0 and 0.8%, P < 0.01; 10 years: 11.9 and 0.8%, P < 0.001). The most important determinant of the development of albuminuria was the metabolic control of diabetes in NIDDM patients during the follow-up, whereas in nondiabetic subjects, the development of albuminuria was related to elevated blood pressure and fasting insulin levels. Baseline and 5-year albuminuria predicted subsequent cardiovascular mortality in diabetic patients, even when adjusted for multiple risk factors. The risk of cardiovascular death in NIDDM patients increased by simultaneous occurrence of hyperinsulinemia and albuminuria. CONCLUSIONS--The frequency of microalbuminuria in patients with NIDDM increases sharply with the duration of diabetes. Chronic hyperglycemia is the main risk factor for microalbuminuria in diabetic patients. Microalbuminuria accompanied by hyperinsulinemia is a powerful predictor of cardiovascular death in NIDDM patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Xu, X. Chen, L. Yan, H. Cheng, and W. Chen Association between (AC)n dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene and diabetic nephropathy: a meta-analysis J. Mol. Endocrinol., May 1, 2008; 40(5): 243 - 251. [Abstract] [Full Text] [PDF]

				J. Xu, E. T Lee, L. G Best, M. Begum, W. C Knowler, R. R Fabsitz, and B. V Howard Association of albuminuria with all-cause and cardiovascular disease mortality in diabetes: the Strong Heart Study The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 334 - 340. [Abstract] [PDF]

				H. Kramer and M. E. Molitch Screening for Kidney Disease in Adults With Diabetes Diabetes Care, July 1, 2005; 28(7): 1813 - 1816. [Full Text] [PDF]

				J. M. Sosenko, M. Kato, and R. B. Goldberg Sensory Function and Albumin Excretion According to Diagnostic Criteria for Diabetes Diabetes Care, July 1, 2004; 27(7): 1716 - 1720. [Abstract] [Full Text] [PDF]

				Polyunsaturated Fatty Acid Consumption May Play a Role in the Onset and Regression of Microalbuminuria in Well-Controlled Type 1 and Type 2 Diabetic People: A 7-year, prospective, population-based, observational multicenter study Diabetes Care, June 1, 2004; 27(6): 1454 - 1457. [Full Text] [PDF]

				A. Moran, W. Palmas, L. Field, J. Bhattarai, J. E. Schwartz, R. S. Weinstock, and S. Shea Cardiovascular Autonomic Neuropathy Is Associated With Microalbuminuria in Older Patients With Type 2 Diabetes Diabetes Care, April 1, 2004; 27(4): 972 - 977. [Abstract] [Full Text] [PDF]

				G. Savage, P. Ewing, H. Kirkwood, and S. Carter Are undiagnosed IGT/IFG and type 2 diabetes common in heart disease and hypertension? The British Journal of Diabetes & Vascular Disease, November 1, 2003; 3(6): 414 - 416. [Abstract] [PDF]

				J. M. Sosenko, D. Hu, T. Welty, B. V. Howard, E. Lee, and D. C. Robbins Albuminuria in Recent-Onset Type 2 Diabetes: The Strong Heart Study Diabetes Care, June 1, 2002; 25(6): 1078 - 1084. [Abstract] [Full Text] [PDF]

				J. Redon, E. Rovira, A. Miralles, R. Julve, and J. M. Pascual Factors Related to the Occurrence of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension Hypertension, March 1, 2002; 39(3): 794 - 798. [Abstract] [Full Text] [PDF]

				R. C.P. Go, R. Desmond, J. M. Roseman, D. S.H. Bell, C. Vanichanan, and R. T. Acton Prevalence and Risk Factors of Microalbuminuria in a Cohort of African-American Women With Gestational Diabetes Diabetes Care, October 1, 2001; 24(10): 1764 - 1769. [Abstract] [Full Text] [PDF]

				B. P. Tabaei, A. S. Al-Kassab, L. L. Ilag, C. M. Zawacki, and W. H. Herman Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, September 1, 2001; 24(9): 1560 - 1566. [Abstract] [Full Text] [PDF]

				A Melville, R Richardson, D Lister-Sharp, and A McIntosh Complications of diabetes: renal disease and promotion of self-management Qual. Saf. Health Care, December 1, 2000; 9(4): 257 - 263. [Full Text]

				C. T. Valmadrid, R. Klein, S. E. Moss, and B. E. K. Klein The Risk of Cardiovascular Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus Arch Intern Med, April 24, 2000; 160(8): 1093 - 1100. [Abstract] [Full Text] [PDF]

				L. Golan, J. D. Birkmeyer, and H. G. Welch The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors Ann Intern Med, November 2, 1999; 131(9): 660 - 667. [Abstract] [Full Text] [PDF]